癌症组织特异性FAM72表达谱定义了一种新的胶质母细胞瘤基因突变特征
该研究利用cBioPortal(含TCGA)数据库对胶质母细胞瘤中FAM72(A-D)进行表达与体细胞突变分析,建立了与增殖标志物MKI67相关的FAM72转录谱,并发现FAM72旁系同源物过表达与有丝分裂细胞周期基因相关,同时鉴定出一组原发性胶质母细胞瘤特异性基因集。
要点
- FAM72旁系同源物在癌细胞中过表达,与有丝分裂细胞周期基因ASP M、KIF14、KIF23、CENPE、CEP55、SGO1和BUB1相关。
- FAM72表达相关性鉴定出原发性胶质母细胞瘤从头通路中的新基因集:SCN9A、MXRA5、ADAM29、KDR、LRP1B和PIK3C2G。
- 新鉴定的原发性胶质母细胞瘤特异性基因突变特征及FAM72可能为诊断预后生物标志物提供新依据,并可能作为潜在治疗靶点。
核心结论
- 新鉴定的原发性胶质母细胞瘤特异性基因突变特征及FAM72可能为胶质母细胞瘤诊断的预后生物标志物提供新依据,并可能作为潜在治疗靶点。
研究设计与样本
- 利用综合人类临床癌症研究数据库cBioPortal(包括癌症基因组图谱TCGA)对胶质母细胞瘤中FAM72(A-D)进行深入的表达和体细胞突变数据分析。
主要发现
- 建立了跨TCGA的FAM72转录谱,该谱与增殖标志物MKI67的表达相关,并呈现以驱动细胞周期的关键基因为代表组织特异性基因突变特征。
- FAM72旁系同源物在癌细胞中过表达,特别与有丝分裂细胞周期基因ASP M、KIF14、KIF23、CENPE、CEP55、SGO1和BUB1相关,从而参与中心体和有丝分裂纺锤体形成。
- FAM72表达相关性在原发性胶质母细胞瘤从头通路中鉴定出一组新的胶质母细胞瘤特异性基因集(SCN9A、MXRA5、ADAM29、KDR、LRP1B和PIK3C2G),这些基因被预定为可行的治疗靶点。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Glioblastoma multiform (GBM) is a neural stem cell (NSC)-derived malignant brain tumor with complex genetic alterations challenging clinical treatments. FAM72 is a NSC-specific protein comprised of four paralogous genes (FAM72 A-D) in the human genome, but its functional tumorigenic significance is unclear. METHODS: We conducted an in-depth expression and somatic mutation data analysis of FAM72 (A-D) in GBM using the comprehensive human clinical cancer study database cBioPortal [including The Cancer Genome Atlas (TCGA)]. RESULTS: We established a FAM72 transcription profile across TCGA correlated with the expression of the proliferative marker MKI67 and a tissue-specific gene-mutation signature represented by pivotal genes involved in driving the cell cycle. FAM72 paralogs are overexpressed in cancer cells, specifically correlating with the mitotic cell cycle genes ASPM, KIF14, KIF23, CENPE, CENPE, CEP55, SGO1, and BUB1, thereby contributing to centrosome and mitotic spindle formation. FAM72 expression correlation identifies a novel GBM-specific gene set (SCN9A, MXRA5, ADAM29, KDR, LRP1B, and PIK3C2G) in the de novo pathway of primary GBM predestined as viable targets for therapeutics. CONCLUSION: Our newly identified primary GBM-specific gene-mutation signature, along with FAM72, could thus provide a new basis for prognostic biomarkers for diagnostics of GBM and could serve as potential therapeutic targets.
引用
- Rahane CS, Kutzner A, Heese K, et al. A cancer tissue-specific FAM72 expression profile defines a novel glioblastoma multiform (GBM) gene-mutation signature. J Neurooncol. 2018. PMID: 30414097. doi:10.1007/s11060-018-03029-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。